Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.83) per share. This is a 50.91 percent decrease over losses of $(0.55) per share from the same period last year.
JP Morgan Downgrades ResMed to Neutral
JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.